ConductScience.org, home

Paper28166181

DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection.

Chandra J and 10 others. J Immunother, 2017. Cited by 51 papers, by iCite.

Cite this record

ConductScience Library. DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection. Papers, record 28166181. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28166181

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection.
PubMed
Journal
J Immunother
PubMed
Year
2017
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
51
iCite
Relative citation ratio, by iCite
1.72
iCite
Revised in PubMed
2018-11-13
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chandra JJanin
2Dutton JLJulie L
3Li BBo
4Woo WPWai-Ping
5Xu YYan
6Tolley LKLynn K
7Yong MMichelle
8Wells JWJames W
9R Leggatt GGraham
10Finlayson NNeil
11Frazer IHIan H

Source PubMed

Download CSV of authors

Topics22

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Graft RejectionMajor topic
Human papillomavirus 16Major topic
Papillomavirus InfectionsMajor topic
Papillomavirus VaccinesMajor topic
Uterine Cervical NeoplasmsMajor topic
Animals
Antibodies, Monoclonal
B7-H1 Antigen
Cell Growth Processes
Female
Humans
Immunity, Cellular
Immunity, Humoral
Mice
Mice, Inbred C57BL
Oncogene Proteins, Viral
Papillomavirus E7 Proteins
Repressor Proteins
Skin
Skin Transplantation
Vaccination
Vaccines, DNA

Source PubMed

Download CSV of topics

References45

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120028654Invariant NKT cells in hyperplastic skin induce a local immune suppressive environment by IFN-gamma production.J Immunol2010https://conductscience.org/library/papers/20028654PubMed
226386540
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
Lancet2015https://conductscience.org/library/papers/26386540PubMed
319180468Epithelial expression of human papillomavirus type 16 E7 protein results in peripheral CD8 T-cell suppression mediated by CD4+CD25+ T cells.Eur J Immunol2009https://conductscience.org/library/papers/19180468PubMed
422204816Decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB characterise T cells from head and neck cancer patients.Immunobiology2012https://conductscience.org/library/papers/22204816PubMed
526616223A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3).Gynecol Oncol2016https://conductscience.org/library/papers/26616223PubMed
622525006Simultaneous immunisation with a Wilms' tumour 1 epitope and its ubiquitin fusions results in enhanced cell mediated immunity and tumour rejection in C57BL/6 mice.Mol Immunol2012https://conductscience.org/library/papers/22525006PubMed
723135914PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.Cancer Res2013https://conductscience.org/library/papers/23135914PubMed
825063870IL-17 suppresses immune effector functions in human papillomavirus-associated epithelial hyperplasia.J Immunol2014https://conductscience.org/library/papers/25063870PubMed
99275369Different susceptibility of cervical keratinocytes containing human papillomavirus to cell-mediated cytotoxicity.Chin Med J (Engl)1996https://conductscience.org/library/papers/9275369PubMed
1019684440Molecular mechanisms of human papillomavirus-induced carcinogenesis.Public Health Genomics2009https://conductscience.org/library/papers/19684440PubMed
1127031095Epithelium Expressing the E7 Oncoprotein of HPV16 Attracts Immune-Modulatory Dendritic Cells to the Skin and Suppresses Their Antigen-Processing Capacity.PLoS One2016https://conductscience.org/library/papers/27031095PubMed
1211738751Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy.Vaccine2001https://conductscience.org/library/papers/11738751PubMed
1314985791Comparison of HPV DNA vaccines employing intracellular targeting strategies.Gene Ther2004https://conductscience.org/library/papers/14985791PubMed
1419933862
Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and -resistant strains of Leishmania donovani.
J Immunol2009https://conductscience.org/library/papers/19933862PubMed
1522540309Enhanced cellular immune response elicited by a DNA vaccine fused with Ub against Mycobacterium tuberculosis.Scand J Immunol2012https://conductscience.org/library/papers/22540309PubMed
168627712Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene.J Virol1996https://conductscience.org/library/papers/8627712PubMed
1725340820HPV16-E7 expression in squamous epithelium creates a local immune suppressive environment via CCL2- and CCL5- mediated recruitment of mast cells.PLoS Pathog2014https://conductscience.org/library/papers/25340820PubMed
1827367787Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review.JAMA Oncol2016https://conductscience.org/library/papers/27367787PubMed
192542578A point mutational analysis of human papillomavirus type 16 E7 protein.J Virol1989https://conductscience.org/library/papers/2542578PubMed
2020003917DNA vaccine against human papillomavirus type 16: modifications of the E6 oncogene.Vaccine2010https://conductscience.org/library/papers/20003917PubMed

See all 45 referencesDownload CSV of references

Cited by39

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 51 citations.

PMIDTitleJournalYearIn PapersSource
42773168Microfluidics-mediated spatial control of mRNA lipid nanoparticles primes translation and enhances vaccine potency.Nat Biomed Eng2026https://conductscience.org/library/papers/42773168PubMed
42646731Preclinical Development of ARV-2001, an Intradermally Administered mRNA-Lipid Nanoparticle Immunotherapeutic for the Treatment of HPV-16-Positive Cervical High-Grade Squamous Intraepithelial Lesions.Vaccines (Basel)2026https://conductscience.org/library/papers/42646731PubMed
42519393Oncolytic virus-mediated remodeling of tumor microenvironment enhances efficacy of an HPV16 E6/E7 mRNA vaccine in an HPV-positive tumor.Mol Ther Oncol2026https://conductscience.org/library/papers/42519393PubMed
42347638Complete Genomes of Human Papillomavirus Type 16 Viruses Isolated from Cases of Cervical Neoplasia and Squamous Cell Carcinomas Followed in Latvia in 2012-2024.Vaccines (Basel)2026https://conductscience.org/library/papers/42347638PubMed
41084861Recombinant lactococcus lactis expressing HPV-16 E6E7 dual antigens for potential cervical cancer treatment enhances dendritic cell vaccines efficacy.Future Microbiol2025https://conductscience.org/library/papers/41084861PubMed
40713852New mouse model based on adenocarcinoma 4T1 cells expressing HPV16 E6 and E7 applied to assess the efficacy of therapeutic and prophylactic E6/E7-based HPV16 vaccines.Infect Agent Cancer2025https://conductscience.org/library/papers/40713852PubMed
39619016Squamous cell carcinoma is associated with reduced IL34 expression, alterations in the Langerhans cell antigen-processing-presentation machinery and poor patient survival.Clin Transl Immunology2024https://conductscience.org/library/papers/39619016PubMed
39339952Toward the Eradication of Herpes Simplex Virus: Vaccination and Beyond.Viruses2024https://conductscience.org/library/papers/39339952PubMed
39035738A phase Ib study to assess the safety of the human papillomavirus DNA vaccine (AMV002) in combination with durvalumab for HPV-associated oropharyngeal squamous cell carcinoma.Front Oncol2024https://conductscience.org/library/papers/39035738PubMed
38919494Oropharyngeal cancer and human papillomavirus: a visualization based on bibliometric analysis and topic modeling.Front Microbiol2024https://conductscience.org/library/papers/38919494PubMed
37675835Full eradication of pre-clinical human papilloma virus-induced tumors by a lentiviral vaccine.EMBO Mol Med2023https://conductscience.org/library/papers/37675835PubMed
37626903Skin-Grafting and Dendritic Cell "Boosted" Humanized Mouse Models Allow the Pre-Clinical Evaluation of Therapeutic Cancer Vaccines.Cells2023https://conductscience.org/library/papers/37626903PubMed
37550734NSP4 as adjuvant for immunogenicity and design of effective therapeutic HPV16 E6/E7/L1 DNA vaccine in tumor-bearing and healthy C57BL/6 mice.BMC Res Notes2023https://conductscience.org/library/papers/37550734PubMed
36497272Caerin 1.1/1.9 Enhances Antitumour Immunity by Activating the IFN-α Response Signalling Pathway of Tumour Macrophages.Cancers (Basel)2022https://conductscience.org/library/papers/36497272PubMed
36455147Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.Clin Cancer Res2023https://conductscience.org/library/papers/36455147PubMed
35445137Caerin 1 Peptides, the Potential Jack-of-All-Trades for the Multiple Antibiotic-Resistant Bacterial Infection Treatment and Cancer Immunotherapy.Biomed Res Int2022https://conductscience.org/library/papers/35445137PubMed
35372036An Update on the Immunotherapy for Oropharyngeal Squamous Cell Carcinoma.Front Oncol2022https://conductscience.org/library/papers/35372036PubMed
35215833Therapeutic DNA Vaccines against HPV-Related Malignancies: Promising Leads from Clinical Trials.Viruses2022https://conductscience.org/library/papers/35215833PubMed
34805788A model of impaired Langerhans cell maturation associated with HPV induced epithelial hyperplasia.iScience2021https://conductscience.org/library/papers/34805788PubMed
34429969
Intratumoral injection of caerin 1.1 and 1.9 peptides increases the efficacy of vaccinated TC-1 tumor-bearing mice with PD-1 blockade by modulating macrophage heterogeneity and the activation of CD8+ T cells in the tumor microenvironment.
Clin Transl Immunology2021https://conductscience.org/library/papers/34429969PubMed

See all 39 cited byDownload CSV of cited by

Genes10

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28166181

GET https://conductscience.org/api/papers/v1/28166181/references?page=2